Chondroitin Sulphate Effective Treatment For Patients With Osteoarthritis
Chondroitin sulfate has been revealed in a new investigation to considerably reduce pain, improve hand function, enhance grip strength and relieve morning stiffness for individuals with osteoarthritis (OA) of the hand, in comparison with patients in the placebo group. Results of the study are available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR). In the U.S., osteoarthritis, the most common form of arthritis, is estimated by the ACR to affect over 27 million adults.
New Gene Linked To Osteoarthritis Found, Making It The Third
Today investigators have revealed a new gene making it only the third to be identified for this painful and debilitating disease connected with osteoarthritis. The disease affects over 40% of people aged 70 years and over. The disease-associated variant, in the gene MCF2L, was found when Wellcome Trust Sanger Institute investigators used information from the 1000 Genomes Project to increase the power of their genome-wide association scan. The initial stage of the original arcOGEN investigation, funded by Arthritis Research UK, compared the genomes of 3, 177 individuals with osteoarthritis with 4, 894 people from the general population and looked at 600, 000 variants.
NICE Approval Of Mepact Mifamurtide For Treating Osteosarcoma Welcomed By Physicians And Patient Groups, UK
Physicians and patient groups welcome the National Institute for Health and Clinical Excellence (NICE) decision to reverse the draft guidance and approve the use of use of Mepact® in their latest appraisal, announced Takeda UK. Mepact® is designed to treat high-grade non-metastatic osteosarcoma in children, adolescents and young adults aged between 2 and 30. Osteosarcoma, a rare and often fatal form of bone cancer, is a highly aggressive disease with approximately 150 new yearly cases in the UK.